Quality is a fundamental building block of Pharmaceutical Analysis and current focus on Quality by Design highlights the importance of building quality into all aspects of the development and commercialisation process. The scientific programme of the PASG "Pharmaceutical Analysis Designed for Quality" meeting will cover diverse aspects of quality within Pharmaceutical Analysis and include presentations on dissolution, forced degradation studies, raman optical activity, the role of the USP, solid state NMR and the ICH guidance documents Q8, Q9 and Q10, as well as workshops and open discussion.

Date:	16-17th April 2007
Location:	Scarman House, Warwick
Application and Fees:	On Monday or Tuesday without accommodation at £ 125 per person On Monday and Tuesday without accommodation at £ 250 per person With accommodation (Mon) at £ 375 per person Limited accommodation is available on Sunday night at £75 (B&B). Please book directly with Scarman House. Note: Dinner is included with accommodation on Monday
For Further Information:	Please contact Michele Sahrle.

	Monday, 16th April 2007 (All Lectures will be held in Lecture Theatre 9 unless otherwise indicated) Pharmaceutical Analysis Designed for Quality Agenda 10:15 Registration and Coffee 10:30 Welcome by PASG Chairman Gareth Pearce, MSD Session 1: Quality by Design, (Chaired by Adrian Parkinson, 3M) 10:35 Overview of ICH Q8 and Q9 Andy Townsend, AstraZeneca 11:35 "Application of the Principles of Quality by Design to Analytical Methods" Phil Borman & Marion Chatfield, GSK 12:30 LUNCH Session 2: Quality by Design, (Chaired by Phil Jupp, Wyeth) Workshops to follow on from morning presentations 13:45 Parallel Workshop on Q8/Q9 Andy Townsend, AstraZeneca & Phil Jupp, Wyeth 13:45 Parallel Workshop on Q8/Q9 (Lecture Theatre 5) Phil Borman, GSK & Jayne James, Sanofi-Aventis 15:15 TEA 15:30 Feedback from workshops & discussion 16:15 ICH Q10 - Pharmaceutical Quality System Neil Wilkinson, AstraZeneca 17:00 PASG Committee Meeting 19:30 DINNER   Monday, 16th April 2007 (All Lectures will be held in Lecture Theatre 6) Biopharm Agenda 10:15 Registration and Coffee 10:30 Welcome to Biopharma meeting Carl Jone, Merck Serono Session 1: Rapid Analytical Methods, (Chaired by Mike Davies, Lonza) 10:35 Lab-on-a-chip for pI measurements Arthur Watson, Convergent 11:35 Rapid Identification and quantification of post translational modifications by UPLC Anna Izzo, Merck Serono 12:30 LUNCH Session 2: Rapid Glycoform Analysis, (Chaired by Peter Whyment, Lilly) 13:45 Rapid HPLC methods Mike Davies, Lonza 14:30 HPLC on-line measurements to control product quality Lance Smallshaw, Lilly 15:15 TEA 15:30 Progress in measuring O-glycosylation in biopharmaceuticals Daryl Fernandes, Ludger 16:15 Rapid N-glycosylation measurements To be confirmed, M-Scan 17:00 PASG Committee Meeting 19:30 DINNER Tuesday, 17th April 2007 (All Lectures will be held in Lecture Theatre 9) Session 3: Pharmaceutical Analysis in QbD, (Chaired by Graham Clarke, BMS) 09:00 Perspectives on Forced Degradation Studies: BMS perspective on Drug Product Forced Degradation Studies Adele Patterson, BMS Forced Degradation Studies: A Perspective on Inhalation Products Nicola Gillott, 3M Practical Approaches to conducting forced degradation studies Keith Parker, AstraZeneca Open Discussion 10:30 COFFEE 10:45 The role of Dissolution in Quality by Design Dónal Murphy, AstraZeneca 11:15 Designing a Quality Dissolution Method Terry Way, USP 11:45 Solid State NMR in Pharmaceutical Development Les Hughes, AstraZeneca 12:15 LUNCH Session 4: Quality, A Broader Perspective, (Chaired by Gareth Pearce, MSD) 13:15 Public Standards for Pharmaceutical Analysis: A USP Perspective Shawn Dressman, USP 14:00 Raman Optical Activity and its uses in the Pharmaceutical Industry Prof George Tranter, Chiral Labs 14:30 PASG Future Objectives Gareth Pearce,MSD Autumn 2007 meeting overview Chairman's closing remarks 15:00 End of meeting   Tuesday, 17th April 2007 (All Lectures will be held in Lecture Theatre 6 unless otherwise indicated) 08:55 Session 3: Progress in Spectroscopic measurements, (Chaired by Lance Smallshaw, Lilly) 09:00 Monitoring changes in carbohydrate quality following process changes Keith Wilson, GSK 09:45 Monitoring Post Translational Modifications by CD, and IR Marco Barba, University of Roma III, Italy 10:30 COFFEE 10:45 Results from HCP/HCD detection programme(PASG / DTI sponsored MfB PC1 project) Anna Hills, National Physical Laboratory Monitoring Post 11:15 Workshop: Future meetings 12:15 LUNCH Session 4: Quality, A Broader Perspective (Chaired by Gareth Pearce, MSD) (Lecture Theatre 9) 13:15 Public Standards for Pharmaceutical Analysis: A USP Perspective Shawn Dressman, USP 14:00 Raman Optical Activity and its uses in the Pharmaceutical Industry Prof George Tranter, Chiral Labs 14:30 PASG Future Objectives Gareth Pearce, MSD Autumn 2007 meeting overview Chairman's closing remarks 15:00 End of meeting